User profiles for Hye Ryun Kim
 | Hye Ryun KimYonsei University Verified email at yuhs.ac Cited by 14048 |
[HTML][HTML] Brigatinib versus Crizotinib in ALK-Positive Non–Small-Cell Lung Cancer
DR Camidge, HR Kim, MJ Ahn, JCH Yang… - … England Journal of …, 2018 - Mass Medical Soc
Background Brigatinib, a next-generation anaplastic lymphoma kinase (ALK) inhibitor, has
robust efficacy in patients with ALK-positive non–small-cell lung cancer (NSCLC) that is …
robust efficacy in patients with ALK-positive non–small-cell lung cancer (NSCLC) that is …
[HTML][HTML] Pembrolizumab or placebo plus etoposide and platinum as first-line therapy for extensive-stage small-cell lung cancer: randomized, double-blind, phase III …
PURPOSE Pembrolizumab monotherapy has shown antitumor activity in patients with small-cell
lung cancer (SCLC). The randomized, double-blind, phase III KEYNOTE-604 study …
lung cancer (SCLC). The randomized, double-blind, phase III KEYNOTE-604 study …
CNS efficacy of osimertinib in patients with T790M-positive advanced non–small-cell lung cancer: data from a randomized phase III trial (AURA3)
…, JY Han, N Katakami, HR Kim… - Journal of Clinical …, 2018 - ascopubs.org
Purpose In patients with epidermal growth factor receptor (EGFR) mutation–positive advanced
non–small-cell lung cancer (NSCLC), there is an unmet need for EGFR–tyrosine kinase …
non–small-cell lung cancer (NSCLC), there is an unmet need for EGFR–tyrosine kinase …
Nivolumab and ipilimumab as maintenance therapy in extensive-disease small-cell lung cancer: CheckMate 451
…, J Baden, D Pandya, P Doshi, HR Kim - Journal of Clinical …, 2021 - ascopubs.org
PURPOSE In extensive-disease small-cell lung cancer (ED-SCLC), response rates to first-line
platinum-based chemotherapy are robust, but responses lack durability. CheckMate 451, …
platinum-based chemotherapy are robust, but responses lack durability. CheckMate 451, …
Brigatinib versus crizotinib in advanced ALK inhibitor–naive ALK-positive non–small cell lung cancer: second interim analysis of the phase III ALTA-1L trial
DR Camidge, HR Kim, MJ Ahn, JCH Yang… - Journal of Clinical …, 2020 - ascopubs.org
PURPOSE Brigatinib, a next-generation anaplastic lymphoma kinase (ALK) inhibitor,
demonstrated superior progression-free survival (PFS) and improved health-related quality of life (…
demonstrated superior progression-free survival (PFS) and improved health-related quality of life (…
[HTML][HTML] PD-L1 expression on immune cells, but not on tumor cells, is a favorable prognostic factor for head and neck cancer patients
To investigate the expression of programmed death-ligand 1 (PD-L1) and immune
checkpoints and their prognostic value for resected head and neck squamous cell cancer (HNSCC). …
checkpoints and their prognostic value for resected head and neck squamous cell cancer (HNSCC). …
[HTML][HTML] Brigatinib versus crizotinib in ALK inhibitor–naive advanced ALK-positive NSCLC: final results of phase 3 ALTA-1L trial
DR Camidge, HR Kim, MJ Ahn, JCH Yang… - Journal of Thoracic …, 2021 - Elsevier
Introduction In the phase 3 study entitled ALK in Lung cancer Trial of brigAtinib in 1st Line (ALTA-1L),
which is a study of brigatinib in ALK inhibitor–naive advanced ALK-positive NSCLC…
which is a study of brigatinib in ALK inhibitor–naive advanced ALK-positive NSCLC…
Antitumor Activity of Amivantamab (JNJ-61186372), an EGFR–MET Bispecific Antibody, in Diverse Models of EGFR Exon 20 Insertion–Driven NSCLC
J Yun, SH Lee, SY Kim, SY Jeong, JH Kim, KH Pyo… - Cancer Discovery, 2020 - AACR
Currently, there are no approved targeted therapies for EGFR Exon20ins–driven NSCLC.
Preclinical data shown here, together with promising clinical activity in an ongoing phase I …
Preclinical data shown here, together with promising clinical activity in an ongoing phase I …
Hyperprogressive disease during PD-1 blockade in patients with advanced hepatocellular carcinoma
Background & Aims Programmed cell death-1 (PD-1) inhibitor treatment can cause
hyperprogressive disease (HPD), but the incidence, outcome, and predictive factors of HPD are …
hyperprogressive disease (HPD), but the incidence, outcome, and predictive factors of HPD are …
[PDF][PDF] Open-Label, Multicenter, Phase II Study of Ceritinib in Patients With Non–Small-Cell Lung Cancer Harboring ROS1 Rearrangement
…, Y La Choi, MJ Lee, M Kim, JH Kim… - Journal of clinical …, 2017 - researchgate.net
… Sun Min Lim,Hye Ryun Kim,Hyo Sup Shim,Joo-Hang Kim, andByoung Chul Cho, Yonsei
University College of Medicine;Yun-Gyoo Lee, Yoon La Choi, and Myung-Ju Ahn …
University College of Medicine;Yun-Gyoo Lee, Yoon La Choi, and Myung-Ju Ahn …